- Institution
- CPMC — Demo
- RCP
- RCP Senology
- Meeting date
- 01/10/2026
- Format
- Hybrid
Patient
- Full name
- Synthetic patient
- Sex
- F · 52 years
- Date of birth
- 27/06/1974
- Case no.
- CPMC-026370
Presentation
- Reason
- Initial case, before any treatment
- Presenting physician
- Dr Nadia Cherif
- Question asked
- Neoadjuvant anti-HER2 treatment?
Calculated data (to verify)
Calculated by the specialty pack from the case
ER status Negative (< 1%) HER2 status HER2 positive Subtype (IHC surrogate) HER2+ / HR− (HER2-enriched) Clinical anatomic stage (AJCC 8) IIA
Participants
Attendance and quorum recorded during the meeting
Quorum reached
Medical oncologist · Breast surgeon · Radiation oncologist · Radiologist · Pathologist
Tumor board proposal
Decision validated in the meeting, form from the specialty pack
Neoadjuvant systemic treatment. Neoadjuvant chemotherapy combined with dual anti-HER2 blockade, then surgery.
- Proposed systemic protocol
- Taxane + trastuzumab + pertuzumab
- Consensus
- Unanimous
- Clinical trial
- No trial proposed
This proposal must be discussed with the patient.
Signature
Signed after re-authentication; the document can no longer be changed
Electronically signed by Pr Karim Bensalem on 01/10/2026
Frozen documentsha256 fingerprint · 9f2c41d7a6e05b38c1f47d2e8a90b6c3 (example value)